Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 664

1.

Utilization, Safety, and Technical Performance of a Telemedicine System for Prehospital Emergency Care: Observational Study.

Felzen M, Beckers SK, Kork F, Hirsch F, Bergrath S, Sommer A, Brokmann JC, Czaplik M, Rossaint R.

J Med Internet Res. 2019 Oct 8;21(10):e14907. doi: 10.2196/14907.

2.

The Gas Phase Infrared Spectra of Xylyl Radicals.

Hirsch F, Flock M, Fischer I, Bakels S, Rijs AM.

J Phys Chem A. 2019 Oct 8. doi: 10.1021/acs.jpca.9b09153. [Epub ahead of print]

PMID:
31593463
3.

OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.

He Y, Zhang X, Jia K, Dziadziuszko R, Zhao S, Deng J, Wang H, Hirsch FR, Zhou C.

Transl Lung Cancer Res. 2019 Aug;8(4):352-366. doi: 10.21037/tlcr.2019.08.15.

4.

EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.

Nicholson AG, Sauter JL, Nowak AK, Kindler HL, Gill RR, Remy-Jardin M, Armato SG 3rd, Fernandez-Cuesta L, Bueno R, Alcala N, Foll M, Pass H, Attanoos R, Baas P, Beasley MB, Brcic L, Butnor KJ, Chirieac LR, Churg A, Courtiol P, Dacic S, De Perrot M, Frauenfelder T, Gibbs A, Hirsch FR, Hiroshima K, Husain A, Klebe S, Lantuejoul S, Moreira A, Opitz I, Perol M, Roden A, Roggli V, Scherpereel A, Tirode F, Tazelaar H, Travis WD, Tsao MS, van Schil P, Vignaud JM, Weynand B, Cree I, Rusch VW, Girard N, Galateau-Salle F.

J Thorac Oncol. 2019 Sep 20. pii: S1556-0864(19)33232-0. doi: 10.1016/j.jtho.2019.08.2506. [Epub ahead of print]

PMID:
31546041
5.

A two-case study of coarticulation in stuttered speech. An articulatory approach.

Didirková I, Hirsch F.

Clin Linguist Phon. 2019 Sep 3:1-19. doi: 10.1080/02699206.2019.1660913. [Epub ahead of print]

PMID:
31478388
6.

Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.

Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK.

J Thorac Oncol. 2019 Oct;14(10):1718-1731. doi: 10.1016/j.jtho.2019.08.012. Epub 2019 Aug 27.

PMID:
31470129
7.

Galectin-9 in non-small cell lung cancer.

He Y, Jia K, Dziadziuszko R, Zhao S, Zhang X, Deng J, Wang H, Hirsch FR, Zhou C.

Lung Cancer. 2019 Oct;136:80-85. doi: 10.1016/j.lungcan.2019.08.014. Epub 2019 Aug 16.

PMID:
31454748
8.

Wie bei Kindern ein gutes Lungen-MRT gelingt.

Hirsch FW, Anders R, Roth C, Gräfe D.

Rofo. 2019 Sep;191(S 02):S114-S115. doi: 10.1055/a-0943-1168. Epub 2019 Aug 20. German. No abstract available.

PMID:
31430776
Free Article
9.

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0327-4. [Epub ahead of print] Review.

PMID:
31383961
10.

Frequency of neuroimaging for pediatric minor brain injury is determined by the primary treating medical department.

Klora M, Zeidler J, Bassler S, Hirsch FW, Gosemann JH, Lacher M, Zimmermann P.

Medicine (Baltimore). 2019 Jul;98(28):e16320. doi: 10.1097/MD.0000000000016320.

11.

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Oct;14(10):1704-1717. doi: 10.1016/j.jtho.2019.06.020. Epub 2019 Jun 28.

PMID:
31260832
12.

Ethics assessment in research proposals adopting CRISPR technology.

Hirsch F, Iphofen R, Koporc Z.

Biochem Med (Zagreb). 2019 Jun 15;29(2):020202. doi: 10.11613/BM.2019.020202. Review.

13.

c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.

Tsakonas G, Botling J, Micke P, Rivard C, LaFleur L, Mattsson J, Boyle T, Hirsch FR, Ekman S.

Lung Cancer. 2019 Jul;133:69-74. doi: 10.1016/j.lungcan.2019.04.028. Epub 2019 May 1.

PMID:
31200831
14.

Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.

Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, Roden AC, Hirsch FR, Wistuba II, Pusztai L.

Breast Cancer Res. 2019 Jun 13;21(1):72. doi: 10.1186/s13058-019-1156-6.

15.

Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer.

Nakajima E, Sugita M, Furukawa K, Takahashi H, Uchida O, Kawaguchi Y, Ohira T, Matsubayashi J, Ikeda N, Hirsch FR, Franklin WA.

Oncol Lett. 2019 Jun;17(6):5125-5131. doi: 10.3892/ol.2019.10157. Epub 2019 Mar 18.

16.

Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.

Fan J, Dai X, Wang Z, Huang B, Shi H, Luo D, Zhang J, Cai W, Nie X, Hirsch FR.

Clin Lung Cancer. 2019 Jul;20(4):e517-e530. doi: 10.1016/j.cllc.2019.04.008. Epub 2019 Apr 25.

17.

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.

Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJ Jr.

J Thorac Oncol. 2019 Aug;14(8):1343-1353. doi: 10.1016/j.jtho.2019.04.029. Epub 2019 May 25. Review.

PMID:
31136816
18.

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Gomez DR, Rimner A, Simone CB 2nd, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K.

J Thorac Oncol. 2019 Jul;14(7):1172-1183. doi: 10.1016/j.jtho.2019.03.030. Epub 2019 May 22. Review.

PMID:
31125736
19.

European Society of Paediatric Radiology 2019 strategic research agenda: improving imaging for tomorrow's children.

Arthurs OJ, van Rijn RR, Granata C, Porto L, Hirsch FW, Rosendahl K.

Pediatr Radiol. 2019 Jul;49(8):983-989. doi: 10.1007/s00247-019-04406-4. Epub 2019 May 21.

20.

Carbon monoxide insertion at a heavy p-block element: unprecedented formation of a cationic bismuth carbamoyl.

Ramler J, Poater J, Hirsch F, Ritschel B, Fischer I, Bickelhaupt FM, Lichtenberg C.

Chem Sci. 2019 Feb 28;10(15):4169-4176. doi: 10.1039/c9sc00278b. eCollection 2019 Apr 21.

21.

ARRIGE Arrives: Toward the Responsible Use of Genome Editing.

Montoliu L, Merchant J, Hirsch F, Abecassis M, Jouannet P, Baertschi B, Sarrauste de Menthière C, Chneiweiss H.

CRISPR J. 2018 Apr;1:128-129. doi: 10.1089/crispr.2018.29012.mon. No abstract available.

22.

[From Xrays to PET/MR, and then? - Future imaging in pediatric radiology].

Staatz G, Daldrup-Link HE, Herrmann J, Hirsch FW, Schäfer JF, Seehofnerova A, Sorantin E, Theruvath AJ, Lollert A.

Rofo. 2019 Apr;191(4):357-366. doi: 10.1055/a-0853-2744. Epub 2019 Mar 21. German.

23.

Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.

Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, Qiao M, Chen X, Su C, Yu H, Zhou C, Zhang J, Camidge DR, Hirsch FR.

Cancer Immunol Res. 2019 Apr;7(4):630-643. doi: 10.1158/2326-6066.CIR-17-0640. Epub 2019 Feb 12.

PMID:
30755403
24.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G, Szustakowski JD, Sasson A, Golhar R, Vitazka P, Chang H, Geese WJ, Antonia SJ.

Cancer Cell. 2019 Feb 11;35(2):329. doi: 10.1016/j.ccell.2019.01.011. No abstract available.

PMID:
30753829
25.

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.

Wang Y, Jiang T, Qin Z, Jiang J, Wang Q, Yang S, Rivard C, Gao G, Ng TL, Tu MM, Yu H, Ji H, Zhou C, Ren S, Zhang J, Bunn P, Doebele RC, Camidge DR, Hirsch FR.

Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542.

PMID:
30596880
26.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
27.

EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

Agustoni F, Suda K, Yu H, Ren S, Rivard CJ, Ellison K, Caldwell C Jr, Rozeboom L, Brovsky K, Hirsch FR.

Cancer Treat Rev. 2019 Jan;72:15-27. doi: 10.1016/j.ctrv.2018.08.002. Epub 2018 Aug 4. Review.

PMID:
30445271
28.

Self-Reaction of ortho-Benzyne at High Temperatures Investigated by Infrared and Photoelectron Spectroscopy.

Hirsch F, Reusch E, Constantinidis P, Fischer I, Bakels S, Rijs AM, Hemberger P.

J Phys Chem A. 2018 Dec 13;122(49):9563-9571. doi: 10.1021/acs.jpca.8b09640. Epub 2018 Dec 3.

PMID:
30444617
29.

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.

Ren S, Tian Q, Amar N, Yu H, Rivard CJ, Caldwell C, Ng TL, Tu M, Liu Y, Gao D, Ellison K, Suda K, Rozeboom L, Rivalland G, Mitchell P, Zhou C, Hirsch FR.

Lung Cancer. 2018 Nov;125:115-120. doi: 10.1016/j.lungcan.2018.09.004. Epub 2018 Sep 12.

PMID:
30429008
30.

TIM-3, a promising target for cancer immunotherapy.

He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR.

Onco Targets Ther. 2018 Oct 16;11:7005-7009. doi: 10.2147/OTT.S170385. eCollection 2018. Review.

31.

EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.

Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X, Li X, Zhao C, Xu Q, Li W, Wu F, Xiong A, Zhao J, Xu Y, Su C, Ren S, Zhou C, Hirsch FR.

Int J Cancer. 2019 May 15;144(10):2605-2612. doi: 10.1002/ijc.31962. Epub 2018 Dec 8.

PMID:
30387880
32.

Risk factors for nicotine dependence in Chinese patients with lung cancer.

Gu F, He Y, Mao Y, Lu S, Zhao C, Li X, Zhou C, Hirsch FR.

J Int Med Res. 2019 Jan;47(1):391-397. doi: 10.1177/0300060518802738. Epub 2018 Oct 10.

33.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE 3rd, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, Boyd Z, Miley N, Flynn S, Leveque V, Shames DS, Ballinger M, Mocci S, Shankar G, Funke R, Hampton G, Sandler A, Amler L, Mellman I, Chen DS, Hegde PS.

Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126. doi: 10.1073/pnas.1802166115. Epub 2018 Oct 8.

34.

Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib.

Ng TL, Yu H, Smith DE, Boyle TA, York ER, Leedy S, Gao D, Aisner DL, Van Bokhoven A, Heasley LE, Hirsch FR, Camidge DR.

Clin Lung Cancer. 2019 Jan;20(1):e39-e51. doi: 10.1016/j.cllc.2018.09.001. Epub 2018 Sep 7.

35.

Simultaneous F18-FDG-PET/MR Optimized Treatment Planning in a Young Patient with Sacro-Coccygeal Chordoma.

Roth C, Sabri O, Kluge R, Fischer L, Monecke A, Wachowiak R, Hirsch FW, Kurch L.

Klin Padiatr. 2018 Oct;230(6):326-327. doi: 10.1055/a-0715-1768. Epub 2018 Oct 1.

PMID:
30273943
36.

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.

Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG.

J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. Review.

PMID:
30268698
37.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
38.

Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.

Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR.

J Thorac Oncol. 2019 Jan;14(1):25-36. doi: 10.1016/j.jtho.2018.09.006. Epub 2018 Sep 22.

PMID:
30253973
39.

Excited state dynamics and time-resolved photoelectron spectroscopy of para-xylylene.

Issler K, Röder A, Hirsch F, Poisson L, Fischer I, Mitrić R, Petersen J.

Faraday Discuss. 2018 Dec 13;212(0):83-100. doi: 10.1039/c8fd00083b.

PMID:
30238117
40.

Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules.

He Y, Ren S, Wang Y, Li X, Zhou C, Hirsch FR.

J Thorac Dis. 2018 Aug;10(8):5080-5085. doi: 10.21037/jtd.2018.07.138.

41.

sLAG-3 in non-small-cell lung cancer patients' serum.

He Y, Wang Y, Zhao S, Zhao C, Zhou C, Hirsch FR.

Onco Targets Ther. 2018 Aug 13;11:4781-4784. doi: 10.2147/OTT.S164178. eCollection 2018.

42.

A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.

Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.

Clin Lung Cancer. 2018 Sep;19(5):450-456. doi: 10.1016/j.cllc.2018.06.004. Epub 2018 Jun 28.

43.

Congenital Diaphragmatic Hernia Presenting with Tension Pneumothorax in a 3-Year-Old Boy.

Balks MF, Gosemann JH, Sorge I, Lacher M, Hirsch FW.

European J Pediatr Surg Rep. 2018 Jan;6(1):e63-e65. doi: 10.1055/s-0038-1667357. Epub 2018 Aug 22.

44.

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, Rozeboom L, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR.

Mol Cancer Ther. 2018 Oct;17(10):2257-2265. doi: 10.1158/1535-7163.MCT-17-1279. Epub 2018 Jul 26.

45.

Stimulus-Triggered Formation of an Anion-Cation Exciplex in Copper(I) Complexes as a Mechanism for Mechanochromic Phosphorescence.

Hupp B, Nitsch J, Schmitt T, Bertermann R, Edkins K, Hirsch F, Fischer I, Auth M, Sperlich A, Steffen A.

Angew Chem Int Ed Engl. 2018 Oct 8;57(41):13671-13675. doi: 10.1002/anie.201807768. Epub 2018 Sep 12.

PMID:
30048568
46.

Impact of crystalline and amorphous iron- and aluminum hydroxides on mechanisms of phosphate adsorption and desorption.

Gypser S, Hirsch F, Schleicher AM, Freese D.

J Environ Sci (China). 2018 Aug;70:175-189. doi: 10.1016/j.jes.2017.12.001. Epub 2017 Dec 12.

PMID:
30037404
47.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS.

J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

48.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R.

J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. Review.

49.

Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions.

Suda K, Kim J, Murakami I, Rozeboom L, Shimoji M, Shimizu S, Rivard CJ, Mitsudomi T, Tan AC, Hirsch FR.

J Thorac Oncol. 2018 Oct;13(10):1496-1507. doi: 10.1016/j.jtho.2018.05.039. Epub 2018 Jun 19.

50.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196.

Supplemental Content

Loading ...
Support Center